A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT05585281 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Fluzoparib
BIOLOGICAL: QL1101

Sponsor

Yongpeng Wang